Author: Author Tina GumbleyPosted on: Posted on May 14, 2016
The shares of Novo Nordisk A/S (ADR) (NYSE:NVO) currently has mean rating of 1.00 while 1 analysts have recommended the shares as “BUY”, Zero recommended as “OUTPERFORM” and Zero recommended as “HOLD”. The rating score is on a scale of 1 to 5 where 1 stands for strong buy and 5 stands for sell.
The company’s mean estimate for sales for the current quarter ending June-16 is 4.30 billion by 1 analysts. The means estimate of sales for the year ending Dec-16 is 17.41 billion by 2 analysts.
The mean price target for the shares of Novo Nordisk A/S (ADR) (NYSE:NVO) is at 60.10 while the highest price target suggested by the analysts is 60.10 and low price target is 60.10. The mean price target is calculated keeping in view the consensus of 1 brokerage firms.
The average estimate of EPS for the current fiscal quarter for Novo Nordisk A/S (ADR) (NYSE:NVO) stands at 0.58 while the EPS for the current year is fixed at 1.33 by 2 analysts.
The next one year’s EPS estimate is set at 1.45 by 2 analysts while a year ago the analysts suggested the company’s EPS at 1.33. The analysts also projected the company’s long-term growth at 11.70% for the upcoming five years.
In its latest quarter ended on 31th March 2016, Novo Nordisk A/S (ADR) (NYSE:NVO) reported earnings of $0.55. In the matter of earnings surprises, the term “Cockroach Effect” is often implied. Cockroach Effect is a market theory that suggests that when a company reveals bad news to the public, there may be many more related negative events that have yet to be revealed. In the case of earnings surprises, if a company is suggesting a negative earnings surprise it means there are more to come.
See Also: THE BIG DROP: HOW TO GROW YOUR WEALTH DURING THE COMING COLLAPSE
On May 3, 2016 Novo Nordisk A/S (ADR) (NVO) announced results from the SCALE™ Obesity and Prediabetes, and SCALE™ Diabetes trials were presented at the 13th International Congress on Obesity (ICO). This post-hoc analysis demonstrated that at 56 weeks, people with obesity or who were overweight with comorbidities and treated with Saxenda®, as an adjunct to a reduced-calorie diet and increased physical activity, had a generally consistent effect on weight loss and certain weight related risk factors across baseline Edmonton Obesity Staging System (EOSS) scores.1 The EOSS is a disease staging system, which ranks severity of obesity based on clinical assessment of weight-related health problems, mental health and physical function.2
At 56 weeks, greater weight loss was seen in people with obesity or who were overweight, with or without type 2 diabetes, treated with Saxenda® compared to placebo consistently across all baseline EOSS scores.1 Additionally, improvements in cardiometabolic risk factors (including HbA1c, systolic blood pressure (SBP) and lipid parameters) and physical function were greater in those treated with Saxenda® compared to placebo, again, consistently across all baseline EOSS scores.1
For this analysis, individuals were assigned a baseline EOSS score ranging from 0-4, based on the available data on obesity-related comorbidities. An EOSS score of 0 indicated no obesity-related comorbidities or risk factors, whereas a score of 4 indicated severe disability due to obesity-related comorbidities or risk factors.
“Rather than using BMI, the traditional measure of obesity, we developed the Edmonton Obesity Staging System as a tool to describe the overall health of people with obesity or who are overweight with the aim of better supporting weight-management decisions in clinical practice.” said Dr Arya Sharma , University of Alberta , Canada and SCALE™ clinical trial investigator. “In this analysis, we saw that Saxenda® led to weight loss and improvements of weight-related comorbidities in people with obesity regardless of the severity of their disease”.